更多开发者作品
The Lancet HIV
更新于 54 分钟前
近期历史最近 100 条记录
| 2024-10-29 | [Personal View] Ending AIDS as a public health threat: the imperative for clear messaging on U=U, viral suppression, and zero risk | Emi E Okamoto, Florence Riako Anam, Solange Baptiste, Mandisa Dukashe, Erika Castellanos, Midnight Poonkasetwattana, Bruce Richman | |
| 2024-10-29 | [Articles] Initiation and continued use of oral pre-exposure prophylaxis among pregnant and postpartum women in South Africa (PrEP-PP): a demonstration cohort study | Dvora Leah Joseph Davey, Rufaro Mvududu, Nyiko Mashele, Kalisha Bheemraj, Nehaa Khadka, Leigh F Johnson, Sarah Schoetz Dean, Pamina Gorbach, Linda-Gail Bekker, Thomas J Coates, Landon Myer | |
| 2024-10-29 | [Feature] Injectable PrEP comes to southern Africa | Roger Pebody | |
| 2024-10-29 | [Comment] Pre-exposure prophylaxis in the perinatal period | Sheree Schwartz, Friday Saidi | |
| 2024-10-29 | [Editorial] Lenacapavir licenses will not deliver on all opportunities | The Lancet HIV | |
| 2024-10-29 | [Articles] Safety and efficacy of iron supplementation with 3 months of daily ferrous sulphate in children living with HIV and mild-to-moderate anaemia in Uganda: a double-blind, randomised, placebo-controlled trial | Anne E P Frosch, Victor Musiime, Christopher Staley, Andrea L Conroy, Diana Rutebarika, Gilbert Ategeka, Sarah E Cusick | |
| 2024-10-29 | [Comment] Iron supplementation among children living with HIV | Ajibola I Abioye, Wafaie W Fawzi | |
| 2024-10-29 | [Articles] Dynamic choice HIV prevention with cabotegravir long-acting injectable in rural Uganda and Kenya: a randomised trial extension | Moses R Kamya, Laura B Balzer, James Ayieko, Jane Kabami, Elijah Kakande, Gabriel Chamie, Nicole Sutter, Helen Sunday, Janice Litunya, Joshua Schwab, John Schrom, Melanie Bacon, Catherine A Koss, Alex R Rinehart, Maya Petersen, Diane V Havlir, SEARCH Cons | |
| 2024-10-29 | [Comment] Another step forward in implementing long-acting PrEP | Quanhathai Kaewpoowat, Michael E Ohl | |
| 2024-10-29 | [Articles] HIV incidence in people receiving government-subsidised pre-exposure prophylaxis in Australia: a whole-of-population retrospective cohort study | Nicholas A Medland, Hamish McManus, Benjamin R Bavinton, Doug Fraser, Michael W Traeger, Andrew E Grulich, Mark A Stoove, Skye McGregor, Jonathan M King, Dash Heath-Paynter, Rebecca J Guy | |
| 2024-10-29 | [Review] Role of HIV self-testing in strengthening HIV prevention services | Ying Zhang, Cheryl C Johnson, Van Thi Thuy Nguyen, Jason J Ong | |
| 2024-10-29 | [Articles] Health impact, budget impact, and price threshold for cost-effectiveness of lenacapavir for HIV pre-exposure prophylaxis in eastern and southern Africa: a modelling analysis | Linxuan Wu, David Kaftan, Rachel Wittenauer, Cory Arrouzet, Nishali Patel, Arden L Saravis, Brian Pfau, Edinah Mudimu, Anna Bershteyn, Monisha Sharma | |
| 2024-10-29 | [Comment] Cost-effectiveness of lenacapavir for PrEP in Africa | Dvora Joseph Davey, Lise Jamieson | |
| 2024-10-29 | [Culture] An eventful conference | Fio Trethewey | |
| 2024-10-01 | [Editorial] Reflections on a decade of The Lancet HIV | The Lancet HIV | |
| 2024-10-01 | [Feature] The London patient—5 years on from identifying himself | Tony Kirby | |
| 2024-10-01 | [Articles] Cognitive performance, neuropsychiatric symptoms, and cerebrospinal fluid viral control following programmatic switch from efavirenz-based to dolutegravir-based antiretroviral therapy in South Africa (CONNECT): a prospective cohort study | Sam Nightingale, Anna J Dreyer, Kevin G F Thomas, Gert van Zyl, Eric Decloedt, Petrus J W Naude, Catherine Orrell, Phumla Sinxadi, Alan Winston, Saye Khoo, John A Joska | |
| 2024-10-01 | [Comment] Antiretroviral efficacy versus neurotoxicity | Graciela Cárdenas | |
| 2024-10-01 | [Articles] Optimising HIV spending in 12 eastern European and central Asian countries: a modelling study | Debra C ten Brink, Anna L Bowring, Rowan Martin-Hughes, Nisaa Wulan, Yinzong Xiao, Kelvin Burke, Tom Tidhar, Tom Walsh, Sherrie L Kelly, Andrew Shattock, Tom Palmer, Corina Maxim, Shufang Zhang, Nick Scott | |
| 2024-10-01 | [Comment] Optimising HIV spending in eastern Europe and central Asia | Gesine Meyer-Rath, Jeffrey W Imai-Eaton | |
| 2024-10-01 | [Articles] Bacterial sexually transmitted infections among men who have sex with men and transgender women using oral pre-exposure prophylaxis in Latin America (ImPrEP): a secondary analysis of a prospective, open-label, multicentre study | Mayara Secco Torres Silva, Thiago Silva Torres, Carolina Coutinho, Ronaldo Ismério Moreira, Iuri da Costa Leite, Marcelo Cunha, Pedro Henrique Amparo da Costa Leite, Carlos F Cáceres, Hamid Vega-Ramírez, Kelika A Konda, Juan Guanira, José Valdez Madruga, | |
| 2024-10-01 | [Comment] Preventing sexually transmitted infections in the age of PrEP | Javier R Lama, Ann Duerr | |
| 2024-10-01 | [Articles] Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration | Nikos Pantazis, Caroline A Sabin, Sophie Grabar, Marc Van der Valk, Inma Jarrin, Ard van Sighem, Laurence Meyer, Christina Carlander, John Gill, Alain Volny Anne, Bruno Spire, Shema Tariq, Fiona Burns, Dominique Costagliola, Elisa Ruiz-Burga, Giota Toulou | |
| 2024-10-01 | [Comment] Untangling the causal ties between antiretrovirals and obesity | Jennifer Manne-Goehler, Mark J Siedner | |
| 2024-10-01 | [Comment] Complex response to HIV and tuberculosis in South Sudan | Antonio Flores, Buai Tut Chol, Jane Alphonse, Tess Hewett | |
| 2024-10-01 | [Viewpoint] The long wait for long-acting HIV prevention and treatment formulations | Willem Daniel Francois Venter, Monica Gandhi, Simiso Sokhela, Kenly Sikwese, Helen Bygrave, Louis Da Gama, Ndiviwe Mphothulo, Lise Jamieson, Mark J Siedner, Anton L Pozniak, Pablo Rojo, Solange L Baptiste, Jacque Wambui, Gesine Meyer-Rath, Brian Honermann | |
| 2024-10-01 | [Position Paper] Analytical treatment interruption in children living with HIV: position statement from the EPIICAL consortium | Louise Kuhn, Shaun Barnabas, Nicola Cotugno, Holly Peay, Philip Goulder, Mark Cotton, Avy Violari, Savita Pahwa, Kavidha Reddy, Alfredo Tagarro, Kennedy Otwombe, Samantha Fry, Paula Vaz, Maria Grazia Lain, Tacilta Nhampossa, Moherndran Archary, Almoustaph | |
| 2024-08-28 | [Articles] Real-world effectiveness and tolerability of switching to doravirine-based antiretroviral therapy in people with HIV: a nationwide, matched, prospective cohort study | Patrick G A Oomen, Ferdinand W N M Wit, Kees Brinkman, Saskia M E Vrouenraets, Tania Mudrikova, Berend J van Welzen, Marc van der Valk, ATHENA National Observational Cohort Study | |
| 2024-08-28 | [Feature] Highlights from the 25th International AIDS Conference | Peter Hayward | |
| 2024-08-28 | [Comment] GHESKIO's model of patient care during civil unrest in Haiti | Marie Marcelle Deschamps, Mongoljin Bat-Erdene, Ann Duerr, Jean William Pape | |
| 2024-08-28 | [Comment] Where does doravirine fit in current antiretroviral therapy? | Phumla Sinxadi, Gary Maartens | |
| 2024-08-28 | [Editorial] A game-changer for PrEP if access is adequate | The Lancet HIV | |
| 2024-08-28 | [Articles] Identifying risk factors for anal cancer in people with HIV in Spain: a multicentre retrospective cohort study nested in the PISCIS cohort | Josep M Llibre, Boris Revollo, Jordi Aceiton, Yesika Díaz, Pere Domingo, Joaquim Burgos, Patricia Sorni, Maria Saumoy, Hernando Knobel, Marta Navarro, Elena Leon, Amat Orti, Laia Arbonés, Arantxa Mera, Elisabet Deig, Guillem Sirera, Josep M Miró, Jordi Ca | |
| 2024-08-28 | [Comment] Optimising anal cancer screening through risk stratification | Elena Sendagorta, Pedro Herranz | |
| 2024-08-28 | [Articles] Impact of financial incentives on viral suppression among adults initiating HIV treatment in Tanzania: a hybrid effectiveness–implementation trial | Prosper F Njau, Emmanuel Katabaro, Solis Winters, Amon Sabasaba, Kassim Hassan, Babuu Joseph, Hamza Maila, Janeth Msasa, Carolyn A Fahey, Laura Packel, William H Dow, Nicholas P Jewell, Nzovu Ulenga, Natalino Mwenda, Sandra I McCoy | |
| 2024-08-28 | [Comment] Incentivising engagement in care among people with HIV | P J Smith, H Thirumurthy | |
| 2024-08-28 | [The Lancet HIV Commissions] IAPAC–Lancet HIV Commission on the future of urban HIV responses | José M Zuniga, Corey Prachniak, Nicoletta Policek, Nombulelo Magula, Anisha Gandhi, Jane Anderson, Dázon Dixon Diallo, Viviane Dias Lima, Sindhu Ravishankar, Shrikala Acharya, Angeli Achrekar, Monsurat Adeleke, Élodie Aïna, Solange Baptiste, Geoffrey Barr | |
| 2024-08-28 | [Culture] No money, no treatment—living on the edge | Talha Burki | |
| 2024-07-30 | [Editorial] US funding for HIV at risk again | The Lancet HIV | |
| 2024-07-30 | [Articles] The contribution of intimate partner violence to vertical HIV transmission: a modelling analysis of 46 African countries | Salome Kuchukhidze, Magdalene K Walters, Dimitra Panagiotoglou, Marie-Claude Boily, Souleymane Diabaté, W Alton Russell, Heidi Stöckl, Lynnmarie Sardinha, Francisco Mbofana, Rhoda K Wanyenze, Jeffrey W Imai-Eaton, Mathieu Maheu-Giroux | |
| 2024-07-30 | [Comment] Addressing partner violence to end infant HIV infection | A M Hatcher, L Kimbo | |
| 2024-07-30 | [Articles] HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial | David A Wohl, Christoph D Spinner, Jason Flamm, C Bradley Hare, Susanne Doblecki-Lewis, Peter J Ruane, Jean-Michel Molina, Anthony Mills, Cynthia Brinson, Moti Ramgopal, Amanda Clarke, Gordon Crofoot, Claudia Martorell, Christoph Carter, Stephanie Cox, J | |
| 2024-07-30 | [Correspondence] Madagascar urgently needs a 2024 national prevalence survey of HIV | Audrey Geoffroy, Luc Samison, Fidiniaina Randriatsarafara, Haja Randriantsara, ZA Randriamanantany, Christophe Vanhecke | |
| 2024-07-30 | [Comment] Novel anti-obesity drugs for people with HIV | Nomathemba Chandiwana, Jennifer Manne-Goehler, Lobna Gaayeb, Alexandra Calmy, Willem D F Venter | |
| 2024-07-30 | [Comment] Reassuring long-term safety, resistance, and efficacy data for two daily formulations of PrEP | Deborah Donnell | |
| 2024-07-30 | [Position Paper] Person-centred care for older adults living with HIV in sub-Saharan Africa | Deborah Goldstein, Jepchirchir Kiplagat, Charlotte Taderera, Erin R Whitehouse, Cleophas Chimbetete, Sylvester Kimaiyo, Sarah Urasa, Stella-Maria Paddick, Catherine Godfrey | |
| 2024-07-30 | [Articles] Potential population-level effects of HIV self-test distribution among key populations in Côte d'Ivoire, Mali, and Senegal: a mathematical modelling analysis | Romain Silhol, Mathieu Maheu-Giroux, Nirali Soni, Arlette Simo Fotso, Nicolas Rouveau, Anthony Vautier, Clémence Doumenc-Aïdara, Olivier Geoffroy, Kouassi Noel N'Guessan, Younoussa Sidibé, Odé Kanku Kabemba, Papa Alioune Gueye, Pauline Dama Ndeye, Christi | |
| 2024-07-30 | [Comment] Effects of self-testing on HIV outcomes in west Africa | Karin Hatzold, Yasmin Dunkley | |
| 2024-07-30 | [Articles] Impact of a point-of-care urine tenofovir assay on adherence to HIV pre-exposure prophylaxis among women in Kenya: a randomised pilot trial | Monica Gandhi, David V Glidden, Deepalika Chakravarty, Guohong Wang, Charlene Biwott, Peter Mogere, Gakuo Maina, Irene Njeru, Catherine Kiptinness, Phelix Okello, Matthew A Spinelli, Purba Chatterjee, Jennifer Velloza, Vallery Ogello, Andrew Medina-Marino | |
| 2024-07-30 | [Comment] Low-cost point-of-care urine test to enhance PrEP adherence | Iuri da Costa Leite, Daniel Savignon Marinho | |
| 2024-07-30 | [Viewpoint] Steatotic liver disease and HIV: an agenda for 2030 | Juan M Pericàs, Anish K Arora, Carlotta Riebensahm, Alba Jiménez-Masip, Adrià Ramírez Mena, Trenton M White, Nikos Dedes, Giovanni Guaraldi, Annalisa Berzigotti, Gilles Wandeler, Meena B Bansal, Jordi Navarro, Jeffrey V Lazarus | |
| 2024-07-30 | [Profile] Mandala: helping combat HIV in Georgia | Ed Holt | |
| 2024-07-30 | [Feature] Legislation threat to services for LGBTQ+ people in Georgia | Ed Holt | |
| 2024-06-25 | [Viewpoint] Is HIV epidemic control by 2030 realistic? | Chris Beyrer, Georgia D Tomaras, Huub C Gelderblom, Glenda E Gray, Holly E Janes, Linda-Gail Bekker, Gregorio Millett, Giuseppe Pantaleo, Susan Buchbinder, Lawrence Corey | |
| 2024-06-25 | [Articles] Effectiveness of integrating HIV prevention within sexual reproductive health services with or without peer support among adolescents and young adults in rural KwaZulu-Natal, South Africa (Isisekelo Sempilo): 2 × 2 factorial, open-label, random | Maryam Shahmanesh, Natsayi Chimbindi, Jacob Busang, Glory Chidumwa, Nondumiso Mthiyani, Carina Herbst, Nonhlanhla Okesola, Jaco Dreyer, Thembelihle Zuma, Manono Luthuli, Dumsani Gumede, Siphesihle Hlongwane, Simphiwe Mdluli, Sithembile Msane, Theresa Smit | |
| 2024-06-25 | [Comment] Integration of sexual health and HIV services | Megan A Hansen, Brooke E Nichols | |
| 2024-06-25 | [Editorial] Long-overdue conclusion to the UK Infected Blood Inquiry | The Lancet HIV | |
| 2024-06-25 | [Feature] UK Infected Blood Inquiry highlights decades of failings | Talha Burki | |
| 2024-06-25 | [Personal View] Moving beyond hotspots of HIV prevalence to geospatial hotspots of UNAIDS 95-95-95 targets in sub-Saharan Africa | Diego F Cuadros, Qian Huang, Godfrey Musuka, Tafadzwa Dzinamarira, Brian K Moyo, Amon Mpofu, Tatenda Makoni, F DeWolfe Miller, Anna Bershteyn | |
| 2024-06-25 | [Articles] Longitudinal evolution of the HIV effective reproduction number following sequential expansion of treatment as prevention and pre-exposure prophylaxis in British Columbia, Canada: a population-level programme evaluation | Viviane D Lima, Jielin Zhu, Rolando Barrios, Junine Toy, Jeffrey B Joy, Brian G Williams, Reuben Granich, Zunyou Wu, Jason Wong, Julio S G Montaner | |
| 2024-06-25 | [Comment] Reducing HIV transmission in British Columbia, Canada | Ann Duerr, Chris Beyrer | |
| 2024-06-25 | [Articles] Transition times across the HIV care continuum in Spain from 2005 to 2022: a longitudinal cohort study | Alejandro G García-Ruiz de Morales, María Jesús Vivancos, María de Lagarde, Margarita Ramírez Schacke, Maria del Mar Arcos Rueda, Eva Orviz, Adrian Curran, Francisco Carmona-Torre, Santiago Moreno, María Jesús Pérez-Elías, Javier Martínez-Sanz, Cohort of | |
| 2024-06-25 | [Comment] Reducing time to viral suppression in Europe | Lise Cuzin, Pascal Pugliese | |
| 2024-06-25 | [Articles] Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, rando | D2EFT Study Group | |
| 2024-06-25 | [Comment] Second-line HIV treatments for adults in LMICs | Esaú C João | |
| 2024-05-29 | [Articles] Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort: a prospective observational cohort study | Maria Salgado, Cristina Gálvez, Monique Nijhuis, Mi Kwon, E Fabian Cardozo-Ojeda, Jon Badiola, Matthew J Gorman, Laura E P Huyveneers, Victor Urrea, Alessandra Bandera, Björn-Erik Ole Jensen, Linos Vandekerckhove, Manuel Jurado, Kavita Raj, Julian Schulze | |
| 2024-05-29 | [Review] Critical illness due to infection in people living with HIV | Guy A Richards, Jarrod Zamparini, Ismail Kalla, Abdullah Laher, Lyle W Murray, Erica J Shaddock, Sarah Stacey, WD Francois Venter, Charles Feldman | |
| 2024-05-29 | [Comment] Responding to the global epidemic of amphetamine-type stimulant use compromising biomedical HIV prevention among men who have sex with men | Adam W Carrico, Leah Davis Ewart, Udi Davidovich, Lisa Maher, Kai J Jonas, Keith J Horvath, Sabina Hirshfield, Thomas E Guadamuz, Tara Carney, Christian Grov | |
| 2024-05-29 | [Comment] Reduction of HIV reservoir after stem cell transplantation | Sharon R Lewin, Jillian Lau | |
| 2024-05-29 | [Editorial] Sex workers are a key population in society | The Lancet HIV | |
| 2024-05-29 | [Comment] Closing the equity gap in the treatment of HIV-2 infection | Sarah Rowland-Jones, Ester Gea-Mallorquí | |
| 2024-05-29 | [Articles] Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open-label, randomised controlled trial | Serge P Eholie, Didier K Ekouevi, Corine Chazallon, Charlotte Charpentier, Eugène Messou, Zelica Diallo, Jacques Zoungrana, Albert Minga, Ndeye Fatou Ngom Gueye, Denise Hawerlander, Fassery Dembele, Géraldine Colin, Boris Tchounga, Sophie Karcher, Jérome | |
| 2024-05-29 | [Articles] Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial | Jean-Michel Molina, Giuliano Rizzardini, Catherine Orrell, Alejandro Afani, Alexandra Calmy, Shinichi Oka, Federico Hinestrosa, Princy Kumar, Pablo Tebas, Sharon Walmsley, Anjana Grandhi, Stephanie Klopfer, Isaias Gendrano, Karen Eves, Todd A Correll, Mic | |
| 2024-05-29 | [Comment] Is this the end of the road for daily islatravir 0·75 mg? | Jennifer Hoy, James McMahon | |
| 2024-05-29 | [Articles] Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-b | Anthony M Mills, Giuliano Rizzardini, Moti N Ramgopal, Olayemi O Osiyemi, Johannes R Bogner, Debbie P Hagins, Roger Paredes, Jacques Reynes, Jürgen K Rockstroh, Andrew Carr, Feng-Hsiu Su, Stephanie O Klopfer, Karen Eves, Rebeca M Plank, Todd Correll, Mich | |
| 2024-05-29 | [Correspondence] Context-specific estimates of vertical transmission | Souleymane Tassembedo, Isidore Tiandiogo Traore, Abdoul-Salam Ouedraogo, Nicolas Meda, Philippe Van de Perre, Nicolas Nagot, Fati Kirakoya-Samadoulougou | |
| 2024-05-29 | [Viewpoint] Two-drug regimens for the treatment of HIV in Africa | Ivan Mambule, Claire Norcross, Loice Achieng Ombajo, Simiso Sokhela, Eva Agnes Laker Odongpiny, Noela Owarwo, David S Lawrence, Eugene Ruzagira, Fiona V Cresswell | |
| 2024-05-29 | [Feature] Tajikistan's tentative steps to tackling HIV | Ed Holt | |
| 2024-05-29 | [Culture] Closeted life of a Hollywood giant | Talha Burki | |
| 2024-04-30 | [Articles] Safety and immunogenicity of a polyvalent DNA–protein HIV vaccine with matched Env immunogens delivered as a prime–boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind rando | Ian Frank, Shuying S Li, Nicole Grunenberg, Edgar T Overton, Samuel T Robinson, Hua Zheng, Kelly E Seaton, Jack R Heptinstall, Mary A Allen, Kenneth H Mayer, Daniel A Culver, Michael C Keefer, Sri Edupuganti, Michael N Pensiero, Vijay L Mehra, Stephen C D | |
| 2024-04-30 | [Correspondence] HIV at a crossroads in Pakistan | Hussain A Raza, Mohummad H R Raja, Muhammad M Khakwani, Bushra Jamil | |
| 2024-04-30 | [Feature] Highlights from CROI 2024 | Peter Hayward | |
| 2024-04-30 | [Comment] DNA and protein HIV vaccines: how should we mix it? | Yves Levy | |
| 2024-04-30 | [Editorial] Another crackdown on LGBTQ+ people in Africa | The Lancet HIV | |
| 2024-04-30 | [Articles] Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study | Carina A Rodriguez, Eva Natukunda, Renate Strehlau, Esme L Venter, Supattra Rungmaitree, Coleen K Cunningham, Umesh Lalloo, Pope Kosalaraksa, Elizabeth HellstrÖm, Afaaf Liberty, Eric J McGrath, Meenu Kaur, Rory Leisegang, Jason T Hindman, Vinicius A Vieir | |
| 2024-04-30 | [Articles] Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, | Dathan M Byonanebye, Mark N Polizzotto, Fernando Maltez, Andri Rauch, Katharina Grabmeier-Pfistershammer, Ferdinand Wit, Stéphane De Wit, Antonella Castagna, Antonella d'Arminio Monforte, Cristina Mussini, Jan-Christian Wasmuth, Eric Fontas, Irene Abela, | |
| 2024-04-30 | [Comment] Expanding options of child-friendly, single-tablet regimens for young children with HIV | Tim R Cressey, Anna Turkova | |
| 2024-04-30 | [Comment] More pressure on integrase strand-transfer inhibitors? | Anton L Pozniak, W D Francois Venter | |
| 2024-04-30 | [Review] Non-suppressible viraemia during HIV-1 therapy: a challenge for clinicians | Andrés Esteban-Cantos, Rocío Montejano, Adriana Pinto-Martínez, Javier Rodríguez-Centeno, Federico Pulido, José R Arribas | |
| 2024-04-30 | [Articles] Voucher incentives to improve viral suppression among HIV-positive people who inject drugs and men who have sex with men in India: a cluster randomised trial | Sunil S Solomon, Allison M McFall, Aylur K Srikrishnan, Vinita Verma, Santhanam Anand, Rifa T Khan, Bhawani Singh Kushwaha, Canjeevaram Vasudevan, Shanmugam Saravanan, Nandagopal Paneerselvam, Muniratnam Suresh Kumar, Chinmoyee Das, David D Celentano, Shr | |
| 2024-04-30 | [Comment] Enhancing HIV care with incentives: one size does not fit all | Sandra I McCoy, Amon Sabasaba | |
| 2024-04-30 | [Comment] Intersectional climate justice, health equity, and HIV | Sarah M Wilson, Griffin Woolley, Chris Hawn, Kate Hoffman, Akhenaton-Andrew D Jones, Cliburn Chan, Sarah V Mudrak, M Umar Qureshi, Ashley Ward, Elizabeth T Knippler, N Lance Okeke, Amy Corneli, Georgia D Tomaras, R Keith Reeves | |
| 2024-04-30 | [Viewpoint] Collective antiretroviral protection: new dimensions of community HIV prevention practices at the intersection of U=U and PrEP | Julien B Brisson, Daniel Grace, Amaya G Perez-Brumer | |
| 2024-04-30 | [Correspondence] Low-cost urine tenofovir assay to triage dolutegravir resistance testing | Tyler Martinson, Jacinta Nwogu-Attah, Matthew Spinelli, Monica Gandhi | |
| 2024-03-26 | [Articles] Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose | Aditya H Gaur, Edmund V Capparelli, Katherine Calabrese, Kristin Baltrusaitis, Mark A Marzinke, Cynthia McCoig, Rodica M Van Solingen-Ristea, Sisinyana Ruth Mathiba, Adeola Adeyeye, John H Moye, Barbara Heckman, Elizabeth D Lowenthal, Shawn Ward, Ryan Mil | |
| 2024-03-26 | [Articles] Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, | Elizabeth D Lowenthal, Jennifer Chapman, Rachel Ohrenschall, Katherine Calabrese, Kristin Baltrusaitis, Barbara Heckman, Dwight E Yin, Allison L Agwu, Conn Harrington, Rodica M Van Solingen-Ristea, Cynthia C McCoig, Adeola Adeyeye, Jared Kneebone, Vasilik | |
| 2024-03-26 | [Correspondence] Treatment-as-prevention and HIV incidence in men who have sex with men | Eline S Wijstma, Manon C Vanbellinghen, Maarten F Schim van der Loeff | |
| 2024-03-26 | [Correspondence] Treatment-as-prevention and HIV incidence in men who have sex with men – Authors' reply | Denton Callander, Mark Stoové, Hamish McManus, Rebecca Guy, TAIPAN investigators | |
| 2024-03-26 | [Comment] Optimising PrEP uptake and use in Peru: no time to lose! | Luis Menacho, Kelika A Konda, Leonid Lecca, Robinson Cabello, Alexander Lankowski, Carlos Benites, Jorge A Gallardo-Cartagena, Ann Duerr, Jorge Sánchez, Jerome T Galea | |
| 2024-03-26 | [Comment] Are we ready for long-acting HIV treatment for adolescents? | Natella Rakhmanina | |
匿名用户只展示最新 100 条榜单历史，更多历史数据请登录后查看，支持时光机按天筛选
Sponsors
